Literature DB >> 10463666

In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections.

V Yardley1, S L Croft.   

Abstract

The activities of four amphotericin B formulations, Fungizone, AmBisome, Amphocil, and Abelcet, were compared in vitro and in vivo against Trypanosoma cruzi infections. In vitro, Fungizone and Amphocil were highly active against T. cruzi Y strain amastigotes in macrophages with 50% effective dose (ED50) values of 0.027-0.028 microg/ml, which were 7-fold and 42-fold more active than AmBisome and Abelcet, respectively. In vitro activities of all formulations against T. cruzi amastigotes in Vero cells were similar, with ED50 values in the range of 2.0-4.2 microg/ml. Acute infections of the T. cruzi Y strain in BALB/c mice were suppressed in all animals by a single 25 mg/kg dose of the liposomal formulation AmBisome. At the same dose, the two other lipid formulations, Amphocil and Abelcet, increased the survival rate but did not suppress infection in all animals.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10463666     DOI: 10.4269/ajtmh.1999.61.193

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  14 in total

1.  Lack of Efficacy of Liposomal Amphotericin B Against Acute and Chronic Trypanosoma cruzi Infection in Mice.

Authors:  Karl V Clemons; Raymond A Sobel; Marife Martinez; Rodrigo Correa-Oliveira; David A Stevens
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

2.  Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors.

Authors:  F S Buckner; J H Griffin; A J Wilson; W C Van Voorhis
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

3.  Salvage treatment with amphotericin B in progressive human alveolar echinococcosis.

Authors:  Stefan Reuter; Andreas Buck; Olaf Grebe; Karin Nüssle-Kügele; Peter Kern; Burkhard J Manfras
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

4.  Effect of amphotericin B on larval growth of Echinococcus multilocularis.

Authors:  Stefan Reuter; Marion Merkle; Klaus Brehm; Peter Kern; Burkhard Manfras
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

5.  It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug.

Authors:  Ana C Mesa-Arango; Liliana Scorzoni; Oscar Zaragoza
Journal:  Front Microbiol       Date:  2012-08-08       Impact factor: 5.640

6.  Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome.

Authors:  Sabrina Cencig; Nicolas Coltel; Carine Truyens; Yves Carlier
Journal:  PLoS Negl Trop Dis       Date:  2011-06-28

7.  Significance of algal polymer in designing amphotericin B nanoparticles.

Authors:  Saurabh Bhatia; Vikash Kumar; Kiran Sharma; Kalpana Nagpal; Tanmoy Bera
Journal:  ScientificWorldJournal       Date:  2014-11-12

8.  Conventional therapy and promising plant-derived compounds against trypanosomatid parasites.

Authors:  Daniela Sales Alviano; Anna Léa Silva Barreto; Felipe de Almeida Dias; Igor de Almeida Rodrigues; Maria do Socorro Dos Santos Rosa; Celuta Sales Alviano; Rosangela Maria de Araújo Soares
Journal:  Front Microbiol       Date:  2012-08-06       Impact factor: 5.640

9.  Synergistic Effect of Lupenone and Caryophyllene Oxide against Trypanosoma cruzi.

Authors:  Glendy Polanco-Hernández; Fabiola Escalante-Erosa; Karlina García-Sosa; María E Rosado; Eugenia Guzmán-Marín; Karla Y Acosta-Viana; Alberto Giménez-Turba; Efraín Salamanca; Luis M Peña-Rodríguez
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-20       Impact factor: 2.629

10.  Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi.

Authors:  Joseph D Planer; Matthew A Hulverson; Jennifer A Arif; Ranae M Ranade; Robert Don; Frederick S Buckner
Journal:  PLoS Negl Trop Dis       Date:  2014-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.